Items tagged with Treatment
TB can emerge after cancer immunotherapy (post)
At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.
Now is the time for shorter all-oral regimens for multidrug-resistant TB (post)
The newly revised WHO guidelines for multidrug-resistant tuberculosis treatment includes major changes from the previous version, published in 2016. Notably, drugs such as bedaquiline, linezolid, and clofazimine are now strongly recommended for the treatment of multidrug-resistant tuberculosis. At the same time, older drugs, such as injectables, ethionamide, and para-aminosalicyclic acid, have been downgraded due to poor effectiveness and side-effect profiles. These new recommendations, if implemented, are expected to have a huge impact globally, increasing access of patients with multidrug-resistant tuberculosis to more effective and safer drug regimens that avoid debilitating side-effects, such as permanent hearing loss.
Antiviral therapy may prevent liver injury in hepatitis B/TB co-infection (post)
Receiving antiviral treatment for hepatitis B (HBV) at the time of tuberculosis (TB) diagnosis reduced hospitalizations as a result of drug-induced liver injury by 56%, indicating that patients with TB and HBV co-infection should be given antiviral treatment for HBV when anti-TB therapy is initiated, according to a study published in Clinical Infectious Diseases.
Successful dolutegravir-based ART for patients with TB/HIV co-infection (post)
Dolutegravir in combination with 2 non-nucleot(s)ide reverse transcriptase inhibitors (NRTIs) is well tolerated and may produce rapid virologic and immunologic responses in patients with tuberculosis (TB) and HIV who have not previously received treatment , according to a study published in Clinical Infectious Diseases.
Low-level delamanid and bedaquiline resistance in extensively drug-resistant TB (post)
In a brief report published in Clinical Infectious Diseases, researchers reported a case of drug resistance against 2 recently approved antitubercular medications: delamanid and bedaquiline. Researchers presented a patient with extensively drug-resistant tuberculosis (TB), and highlighted the potential for the emergence and transmission of resistant Mycobacterium tuberculosis complex strains with more frequent use of these relatively new drugs.
Improving the use of methadone for drug users with TB to prevent withdrawal (post)
— Study finds higher dosages of methadone needed while on rifampicin
— Clinicians will be able to use the study as a guide for treatment for their patients
— Researchers developed and tested a ‘virtual clinical trial’ to simulate and test drug interaction
Researchers study resistance to ‘protect’ anti-TB drug (post)
Scientists from Stellenbosch University are trying to conserve the life-saving treatment bedaquiline, by studying how the bacterium that causes TB can develop resistance to this drug.
Sun-exposed oyster mushrooms help patients fight TB (post)
Baltimore (June 9, 2019) - Tuberculosis (TB) remains one of the deadliest infectious diseases in low income countries, with around 1.6 million people dying of the disease each year. In a new study, researchers show that sun-exposed oyster mushrooms offer a readily available source of vitamin D that can help TB patients respond better to anti-TB drugs by improving immune response.
Evotec receives $23.8 million grant to join the global fight against TB (post)
- The Bill & Melinda Gates Foundation Supports Evotec With A $ 23.8 M Grant To Generate Critical Data For Selecting Best Drug Combinations For Phase II Clinical Trials
- Tuberculosis Is The Leading Cause Of Death Due To An Infectious Disease Worldwide
- Five-Year Partnership Is Focused On Evaluating New Treatment Regimens That Can Substantially Reduce Treatment Time And Overcome Resistance To Current Therapies
HAMBURG, GERMANY, June 10, 2019 /Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.
New milestone for children with TB reached as one million treatments of child-friendly medicines are ordered (post)
SYDNEY (June 18, 2019)—TB Alliance today announced that one million treatment courses of child-friendly tuberculosis (TB) medicines have been ordered by 93 countries in the three years since introduction of the products.1 The new medicines, which were first introduced nationally in Kenya in September 2016, are easier for caregivers to administer and for children to take. The announcement took place at the first International Global Health Security Conference in Sydney.
Page 48 of 105 · Total posts: 0
←First 47 48 49 Last→